Tempus AI has launched the ArteraAI Prostate Test (mHSPC), the first externally developed digital pathology algorithm integrated into the Tempus clinical ecosystem. The AI-powered, CLIA-certified assay combines histopathology, clinical data, and genomic insights to improve risk stratification and guide personalized therapy intensity decisions for patients with metastatic hormone-sensitive prostate cancer.
The Oncologic Drugs Advisory Committee (ODAC) voted 7 to 1, with one abstention, that the regimen demonstrated a favorable benefit-risk profile for AstraZeneca’s TRUQAP (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) for patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC). The recommendation, based on results from the phase 3 CAPItello-281 trial, highlights […]
The combination of talazoparib (Talzenna) and enzalutamide (Xtandi) significantly improved radiographic progression-free survival (rPFS) in patients with homologous recombination repair (HRR) gene-mutated metastatic castration-sensitive prostate cancer (mCSPC) in the Phase III TALAPRO-3 trial. The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression or death […]
FDA approves Akeega (niraparib + abiraterone acetate with prednisone) for BRCA2-mutated metastatic castration-sensitive prostate cancer, showing significant improvements in radiographic progression-free survival and delayed symptomatic progression, with a safety profile consistent with the individual therapies.
FDA approves darolutamide (Nubeqa) for mCSPC: 46% reduction in disease progression risk vs placebo in ARANOTE trial.
PSA nadir <0.2 ng/mL within 9 months shows 54% lower death risk vs 22% for ≥90% decline in mCSPC veterans receiving ADT-based therapy.